

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**PCT/PTO 17 SEP 2001**

#5

In re Application of  
**MARCIREAU ET AL.**

Examiner: UNASSIGNED

Art Unit: UNASSIGNED

Serial No.: **09/744,125**

Filed: JANUARY 19, 2001

Title: **MEKK1-INTERACTING FHA  
PROTEIN (M1F1)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as regular mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

September 13, 2001

Date of Deposit

Signature

*Kapadia*

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

*William C. Coppola*

William C. Coppola, Reg. No. 41,686  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4854  
Telefax (908) 231-2626

Docket No. A3233A US